Hanifah Rahmi Fajrin^1,2, Se Dong Min^1,3,*

CMC-Computers, Materials & Continua, Vol.86, No.3, 2026, DOI:10.32604/cmc.2025.072609 - 12 January 2026

Abstract Accurate segmentation of breast cancer in mammogram images plays a critical role in early diagnosis and treatment planning. As research in this domain continues to expand, various segmentation techniques have been proposed across classical image processing, machine learning (ML), deep learning (DL), and hybrid/ensemble models. This study conducts a systematic literature review using the PRISMA methodology, analyzing 57 selected articles to explore how these methods have evolved and been applied. The review highlights the strengths and limitations of each approach, identifies commonly used public datasets, and observes emerging trends in model integration and clinical relevance. More >

Ishaani Priyadarshini^*

CMC-Computers, Materials & Continua, Vol.86, No.3, 2026, DOI:10.32604/cmc.2025.072343 - 12 January 2026

Abstract Early and accurate detection of bone cancer and marrow cell abnormalities is critical for timely intervention and improved patient outcomes. This paper proposes a novel hybrid deep learning framework that integrates a Convolutional Neural Network (CNN) with a Bidirectional Long Short-Term Memory (BiLSTM) architecture, optimized using the Firefly Optimization algorithm (FO). The proposed CNN-BiLSTM-FO model is tailored for structured biomedical data, capturing both local patterns and sequential dependencies in diagnostic features, while the Firefly Algorithm fine-tunes key hyperparameters to maximize predictive performance. The approach is evaluated on two benchmark biomedical datasets: one comprising diagnostic data… More >

Chee Chin Lim^1,2,*, Hui Wen Tiu¹, Qi Wei Oung^1,3, Chiew Chea Lau⁴, Xiao Jian Tan^2,5

CMC-Computers, Materials & Continua, Vol.86, No.3, 2026, DOI:10.32604/cmc.2025.070468 - 12 January 2026

Abstract Breast cancer remains one of the leading causes of cancer mortality world-wide, with accurate molecular subtyping is critical for guiding treatment and improving patient outcomes. Traditional molecular subtyping via immuno-histochemistry (IHC) test is invasive, time-consuming, and may not fully represent tumor heterogeneity. This study proposes a non-invasive approach using digital mammography images and deep learning algorithm for classifying breast cancer molecular subtypes. Four pretrained models, including two Convolutional Neural Networks (MobileNet_V3_Large and VGG-16) and two Vision Transformers (ViT_B_16 and ViT_Base_Patch16_Clip_224) were fine-tuned to classify images into HER2-enriched, Luminal, Normal-like, and Triple Negative subtypes. Hyperparameter tuning,… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077268 - 30 December 2025

Abstract This article has no abstract. More >

Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Cheng-Hsun Chuang^1,2,3,#, Ping-Kun Tsai^3,4,5,6,#, Shih-Wen Kao^7,8, Yu-Hsun Wang^8,9,*, Chao-Bin Yeh^1,2,3,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072875 - 30 December 2025

Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI). Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user… More > Graphic Abstract

Abdulrahman K. Sinno¹, Aisha Mustapha¹, Navya Nair¹, Simona Zaami², Lina De Paola², Valentina Billone³, Eleonora Conti³, Giuseppe Gullo^3,*, Pasquale Patrizio⁴

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072176 - 30 December 2025

Abstract Cervical cancer related to human papillomavirus (HPV) is a leading cause of cancer-related mortality among women worldwide. Cancer cells release fragments of their DNA, known as circulating tumor DNA (ctDNA), which can be detected in bodily fluids. A PubMed search using the terms “ctHPV” or “circulating tumor DNA” and “cervical cancer”, limited to the past ten years, identified 104 articles, complemented by hand-searching for literature addressing medico-legal implications. Studies were evaluated for relevance and methodological quality. Detection and characterization of circulating tumor HPV DNA (ctHPV DNA) have emerged as promising tools for assessing prognosis and More >

Dongchi Cai^1,2,#, Jialin Ji^3,#, Chunhui Yang^1,*, Hong Cai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152 - 30 December 2025

Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

Jing Shan¹, Catherine King^2,3, Harunor Rashid^3,4, Veysel Kayser^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070851 - 30 December 2025

Abstract Objectives: B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM. Methods: A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I… More >

Sarra B. Shakartalla^1,2,3, Iman M. Talaat^1,2,4,*, Nival Ali¹, Shahenaz S. Salih^1,5, Zainab M. Al Shareef^1,2, Noura Alkhayyal⁶, Riyad Bendardaf^2,7,*, Sameh S. M. Soliman^1,8,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070808 - 30 December 2025

Abstract Objectives: Breast cancer (BC) is the leading cause of cancer-related mortality in women, largely due to metastasis. This study aims to explore the role of purine nucleoside phosphorylase (PNP), a key enzyme in purine metabolism, in the aggressiveness and metastatic behavior of BC. Methods: A comprehensive analysis was performed using in silico transcriptomic data (n = 2509 patients), immunohistochemical profiling of BC tissues (n = 103), and validation through western blotting in multiple BC cell lines. Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and… More >